|
|
|
India News Releases
|
(India.CityRegions.Com, June 09, 2017 ) Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Diabetic Macular Edema - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 20, 5, 1, 18 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/diabetic-macular-edema-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001689453/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Aciont Inc
ActiveSite Pharmaceuticals Inc
Acucela Inc
Aerpio Therapeutics Inc
Allergan Plc
Ampio Pharmaceuticals Inc
Araim Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Cell Medica Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chong Kun Dang Pharmaceutical Corp
Clearside BioMedical Inc
Coherus BioSciences Inc
EyeGate Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Formycon AG
Genmab A/S
GlaxoSmithKline Plc
Icon Bioscience Inc
Kala Pharmaceuticals Inc
Kalvista Pharmaceuticals Ltd
Kowa Company Ltd
Lupin Ltd
Mabion SA
Oculis ehf
Ohr Pharmaceutical Inc
Oxular Ltd
Pfizer Inc
pSivida Corp
Regeneron Pharmaceuticals Inc
Santen Pharmaceutical Co Ltd
SciFluor Life Sciences LLC
Senju Pharmaceutical Co Ltd
Stealth BioTherapeutics Inc
ThromboGenics NV
Verseon Corp
Xbrane Biopharma AB
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001689453/discount
List of Tables
Number of Products under Development for Diabetic Macular Edema, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Diabetic Macular Edema - Pipeline by Aciont Inc, H1 2017
Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals Inc, H1 2017
Diabetic Macular Edema - Pipeline by Acucela Inc, H1 2017
Diabetic Macular Edema - Pipeline by Aerpio Therapeutics Inc, H1 2017
Diabetic Macular Edema - Pipeline by Allergan Plc, H1 2017
Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals Inc, H1 2017
Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals Inc, H1 2017
Diabetic Macular Edema - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Diabetic Macular Edema - Pipeline by Cell Medica Ltd, H1 2017
Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2017
Diabetic Macular Edema - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
Diabetic Macular Edema - Pipeline by Clearside BioMedical Inc, H1 2017
Diabetic Macular Edema - Pipeline by Coherus BioSciences Inc, H1 2017
Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals Inc, H1 2017
Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Diabetic Macular Edema - Pipeline by Formycon AG, H1 2017
Diabetic Macular Edema - Pipeline by Genmab A/S, H1 2017
Diabetic Macular Edema - Pipeline by GlaxoSmithKline Plc, H1 2017
Diabetic Macular Edema - Pipeline by Icon Bioscience Inc, H1 2017
Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals Inc, H1 2017
Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Ltd, H1 2017
Diabetic Macular Edema - Pipeline by Kowa Company Ltd, H1 2017
Diabetic Macular Edema - Pipeline by Lupin Ltd, H1 2017
Diabetic Macular Edema - Pipeline by Mabion SA, H1 2017
Diabetic Macular Edema - Pipeline by Oculis ehf, H1 2017
Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc, H1 2017
Diabetic Macular Edema - Pipeline by Oxular Ltd, H1 2017
Diabetic Macular Edema - Pipeline by Pfizer Inc, H1 2017
Diabetic Macular Edema - Pipeline by pSivida Corp, H1 2017
Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Diabetic Macular Edema - Pipeline by Santen Pharmaceutical Co Ltd, H1 2017
Diabetic Macular Edema - Pipeline by SciFluor Life Sciences LLC, H1 2017
Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co Ltd, H1 2017
Diabetic Macular Edema - Pipeline by Stealth BioTherapeutics Inc, H1 2017
Diabetic Macular Edema - Pipeline by ThromboGenics NV, H1 2017
Diabetic Macular Edema - Pipeline by Verseon Corp, H1 2017
Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H1 2017
Diabetic Macular Edema - Dormant Projects, H1 2017
Diabetic Macular Edema - Dormant Projects, H1 2017 (Contd..1), H1 2017
Diabetic Macular Edema - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001689453/buy/2000
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
|
|
|
|
India RSS Feed Marketpalce
|
India News Headlines
Daily news from India: arts, business, culture, politics, science, technology & more.
Free Sales & Marketing Magazines
Get free publications about marketing, sales and customer relations management.
Submit RSS feed on India.
Have your feed on news, products or services displayed under this marketpalce and have your feed on a full page updated daily.
|
|
|
India Business News by Major Cities
|
|
|
|
Listen to GroupWeb Radio
INDIA BUSINESS TV
|
